Developing Standardized Animal Models to Evaluate SARS-Cov-2 Vaccine Effectiveness

coronovirus in conversation banner

Developing Standardized Animal Models to Evaluate SARS-CoV-2 Vaccine Effectiveness 

As the number of SARS-CoV-2 cases exceed 4.1 million and vaccine development efforts are ramped up at unprecedented speed, one pertinent challenge faced by vaccine developers is the lack of standardized animal models. As part of the Corona360 – In Conversation series, the Developing Standardized Animal Models to Evaluate SARS-Cov-2 Vaccine Effectiveness live moderated discussion aims at addressing obstacles faced by 50 companies which are in the pre-clinical study phase.

Interview Details

28th May 2020, Thursday

10:30:00 (GMT +8:00)

Register Now

Add to Calendar

  • Scientists and researchers working on SARS-CoV-2 vaccine development from BIG Pharmas, vaccine manufacturers and research institutions.
  • CROs, technology / service providers and logistics partners keen on understanding how they can alleviate the challenges faced in the development chain.
  • Strategies to address SARS-CoV-2 vaccine development challenges from the get-go.
  • How CROs, technology / service providers and logistics partners may step in to fill the gaps in SARS-CoV-2 vaccine development chain.
  • Recommendations on how lessons learnt from this experience can be applied to other emerging infectious diseases and future pandemics.

Meet Our Panelists

Bing Wang, COO, Shanghai RNAcure Biopharma, China

Jeeri R. Reddy, President, & Scientific Director, JN-International Medical Corporation, USA

S.D. Ravetkar, Executive Director, Serum Institute of India, India

Nikolai Petrovksy, Chairman and Chief Scientific Officer, Vaxine Pty Ltd, Australia

Key Discussion Points

  • Perspectives on pre-clinical testing of SARS-CoV-2 vaccines.
  • Pre-clinical development challenges of SARS-CoV-2 in biological assay development and evaluating SARS-CoV-2 vaccine effectiveness.
  • Lessons learnt from the pre-clinical development of SARS-CoV and MERS-CoV vaccine development.

Market Intelligence